LYMEVAC
How to obtain an effective canine vaccine acting on the spread of Borrelia
Project description
The team at the Institute of Bacteriology has identified important antigens during early transmission in mice as potential vaccine candidates against Lyme disease for veterinary use, with the possibility of transposing them to humans if successful.
Today, all vaccines available for animals block the transmission of the bacterium very early on, by acting in the tick.
The selected LymeVac candidates, on the other hand, have the particularity of acting when inoculation has already taken place, at the time of dissemination.
Why does Conectus invest in this project?
Conectus' financial investment will allow:
- validation of vaccine candidates on the dog model
- antigen production
- the vaccination trial on dogs.
At the origin of the project:
Professor Nathalie Boulanger of the Institute of Bacteriology of the University Hospital of Strasbourg (Research Unit: Early bacterial virulence - cellular functions and control of acute and subacute infection (VBP) - EA 7290), with the National Reference Centre of Borrelia.
Focus
Conectus is investing in this project: 320 000 €.
Duration: 18 months